In this video interview, David Morton, PhD, director of biostatistics at Certara, reflects on the growing role of Bayesian approaches in modern drug development, emphasizing their potential to improve ...
In today's ACT Brief, we explore the operational capabilities clinical teams need to implement Bayesian trial designs, why gender diversity strengthens data science across drug development, and the ...
Public-private collaboration and structured evidence consolidation are emerging as critical enablers of regulatory-ready digital endpoints, helping standardize terminology, reduce duplication, and ...
In today’s ACT Brief, we highlight how Bayesian methods are reshaping adaptive trial design, a major eSource partnership is ...
The Patient Advocate Foundation and the PAN Foundation have announced a strategic merger to create the nation’s most ...
Closing the gender gap in data science and tech requires tackling barriers at every stage, from early education through career advancement, while actively challenging the unconscious biases that ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...
In today’s ACT Brief, we examine how the Verana Health-COTA merger is evolving real-world data use, the FDA’s new framework ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is encouraging sponsors to move beyond traditional methods, leveraging Bayesian ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
At SCOPE Summit 2026, site leaders shared how AI is transforming feasibility, patient identification, and enrollment ...
Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results